Workflow
Zimmer Biomet(ZBH)
icon
Search documents
Zimmer Biomet to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Prnewswire· 2024-12-20 12:30
WARSAW, Ind., Dec. 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT (11:15 a.m. ET). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference. About Zimmer Bio ...
Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2024
Prnewswire· 2024-12-18 12:00
WARSAW, Ind., Dec. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2024. The cash dividend of $0.24 per share is payable on or about January 31, 2025 to stockholders of record as of the close of business on December 30, 2024. About Zimmer Biomet  Zimmer Biomet is a global medical technology leader with a com ...
ZBH Stock Might Rise Following FDA Nod for OsseoFit
ZACKS· 2024-12-16 13:36
Zimmer Biomet Holdings, Inc. (ZBH) recently received Food and Drug Administration ("FDA") 510(k) clearance for the OsseoFit Stemless Shoulder System for total shoulder replacement. The system is designed to match the natural humeral (upper shoulder bone) anatomy to optimize anatomical fit while maximizing the preservation of healthy bone. The OsseoFit Stemless Shoulder System expands the company's expansive total shoulder portfolio. The company plans to launch the system commercially in the first quarter of ...
ZBH Stock Might Rise Following FDA Nod for Knee Implant Component
ZACKS· 2024-12-05 13:55
Company Developments - Zimmer Biomet Holdings Inc (ZBH) received FDA 510(k) clearance for its Persona SoluTion PPS Femur, a total knee implant component designed for patients with sensitivities to bone cement and/or metal [1] - The company expects to commercially launch Persona SoluTion PPS Femur in the United States in Q1 2025 [1] - ZBH recently received FDA Premarket Approval Application Supplement approval for the Oxford Cementless Partial Knee, making it the only FDA-approved cementless partial knee implant in the United States [8] Product Details - Persona SoluTion PPS Femur combines cementless fixation with PPS coating, providing initial scratch fit stability and supporting biological fixation through bony growth [5] - The implant minimizes common metal sensitizers by combining with Persona OsseoTi tibia and Vivacit-E Highly Crosslinked Polyethylene (HXLPE) [6] - The implant is made of Tivanium (Ti-6Al-4V) alloy with over 17 years of clinical use, treated with the Ti-Nidium Surface Hardening Process [6] Market Performance - ZBH shares moved 0.1% lower to $110.62 following the announcement [2] - The company has a market capitalization of $22.09 billion [3] - ZBH shares have lost 4.5% in the past year, compared to the industry's 21% growth [9] Financial Performance - ZBH's earnings surpassed estimates in three of the trailing four quarters, with an average surprise of 1.76% [3] Industry Outlook - The global knee replacement market is expected to reach $16.99 billion by 2031, growing at a CAGR of 5.67% during 2024-2031 [7] - Key growth drivers include rising incidence of osteoarthritis and increasing demand for joint replacement surgeries [7]
ZBH Stock Gains From FDA Nod for Oxford Cementless Partial Knee
ZACKS· 2024-11-26 15:35
Zimmer Biomet Holdings, Inc. (ZBH) recently received Food and Drug Administration (“FDA”) Premarket Approval Application (“PMA”) Supplement approval for the Oxford Cementless Partial Knee. The approval is based on safety and effectiveness data from an Investigational Device Exemption (“IDE”) study and non-clinical testing for cementless partial knee replacement (“PKR”).With this, Oxford Cementless Partial Knee becomes the only FDA-approved cementless partial knee implant in the United States. The latest FDA ...
Zimmer Biomet Receives FDA Approval for Oxford® Cementless Partial Knee, Only Cementless Partial Knee Replacement Implant in the U.S.
Prnewswire· 2024-11-25 21:05
WARSAW, Ind., Nov. 25, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) Premarket Approval Application (PMA) Supplement approval for the Oxford® Cementless Partial Knee. The approval is based on safety and effectiveness data from an Investigational Device Exemption (IDE) study and non-clinical testing for cementless partial knee replacement (PKR).1 The Oxford Cementless Partial Knee allows surge ...
Zimmer Biomet Announces CE Mark Certification for Persona® Revision Knee System
Prnewswire· 2024-11-18 12:30
WARSAW, Ind., and ZURICH, Nov. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision Knee System. This addition to the Persona family builds on Zimmer Biomet's commitment to personalized solutions, providing surgeons with advanced tools for revision knee arthroplasty. Persona Revision Knee System "After the successful introduction of Persona Revision Knee in the United States and other mar ...
ZBH Stock to Gain Support From Market Share Gains Amid Macro Issues
ZACKS· 2024-11-11 16:25
Zimmer Biomet's (ZBH) strategic product launches and stabilizing market trends bolster our confidence in this stock. Yet, factors like macroeconomic uncertainties put pressure on the bottom line. The stock carries a Zacks Rank #3 (Hold).Factors Driving ZBH's Share PriceZimmer Biomet is witnessing strong market share gains within the reconstructive Knees and Hips in key geographies in recent times despite macroeconomic challenges. The third quarter of 2024 marks the 11th consecutive quarter in which Zimmer B ...
Zimmer Biomet(ZBH) - 2024 Q3 - Quarterly Report
2024-10-30 20:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2024 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 345 East Main Street, Warsaw, IN 46580 (Address of princip ...
ZBH Stock Up Despite Q3 Earnings Miss, 2024 View Narrowed
ZACKS· 2024-10-30 15:56
Zimmer Biomet Holdings, Inc. (ZBH) posted third-quarter 2024 adjusted earnings per share (EPS) of $1.74, missing the Zacks Consensus Estimate by 0.6%. However, the adjusted figure increased 5.5% year over year. The quarter's adjustments included certain amortization, restructuring and other cost reduction initiatives and European Union Medical Device Regulation-related charges, among others. On a reported basis, the company registered earnings of $1.23 per share, compared to 77 cents in the year-ago period. ...